XNASBTAI
Market cap17mUSD
Dec 24, Last price
0.35USD
1D
1.36%
1Q
-33.28%
IPO
-96.81%
Name
BioXcel Therapeutics Inc
Chart & Performance
P/E
—
P/S
12.63
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
14.86%
Rev. gr., 5y
%
Revenues
1m
+268.00%
Net income
-179m
L+4.19%
CFO
-155m
L+14.53%
Earnings
Mar 10, 2025
Profile
BioXcel Therapeutics, Inc. is a commercial-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. Its commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. The company also continues to conduct clinical trials evaluating BXCL501 for the treatment of agitation in Alzheimer's disease patients, and for adjunctive treatment of patients with major depressive disorder, as well as in the community for agitation associated with bipolar disorders and schizophrenia. In addition, it is developing BXCL502 as a potential therapy for chronic agitation in dementia; and BXCL701, an investigational, orally administered, systemic innate immunity activator for the treatment of aggressive forms of prostate cancer and advanced solid tumors that are refractory or treatment naïve to checkpoint inhibitors. The company was incorporated in 2017 and is headquartered in New Haven, Connecticut.
IPO date
Mar 08, 2018
Employees
183
Domiciled in
US
Incorporated in
US
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | |
| Income | |||||||||
Revenues | 1,380 268.00% | 375 | |||||||
Cost of revenue | 168,999 | 173,026 | 107,232 | ||||||
Unusual Expense (Income) | |||||||||
NOPBT | (167,619) | (172,651) | (107,232) | ||||||
NOPBT Margin | |||||||||
Operating Taxes | 6,092 | (301) | |||||||
Tax Rate | |||||||||
NOPAT | (167,619) | (178,743) | (106,931) | ||||||
Net income | (179,053) 4.19% | (171,849) 61.16% | (106,630) 30.02% | ||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | 27,032 | 102,447 | |||||||
BB yield | -31.46% | -19.11% | |||||||
| Debt | |||||||||
Debt current | 346 | 319 | 293 | ||||||
Long-term debt | 101,478 | 94,942 | 2,503 | ||||||
Deferred revenue | |||||||||
Other long-term liabilities | 1,905 | 2,343 | |||||||
Net debt | 36,603 | (98,464) | (230,172) | ||||||
| Cash flow | |||||||||
Cash from operating activities | (155,006) | (135,341) | (82,153) | ||||||
CAPEX | (20) | (139) | (445) | ||||||
Cash from investing activities | (20) | (139) | (445) | ||||||
Cash from financing activities | 26,522 | 96,237 | 102,447 | ||||||
FCF | (167,031) | (178,262) | (106,688) | ||||||
| Balance | |||||||||
Cash | 65,221 | 193,725 | 232,968 | ||||||
Long term investments | |||||||||
Excess cash | 65,152 | 193,706 | 232,968 | ||||||
Stockholders' equity | (590,568) | (411,517) | (245,760) | ||||||
Invested Capital | 637,349 | 584,709 | 468,523 | ||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | 29,129 | 28,015 | 26,373 | ||||||
Price | 2.95 -86.27% | 21.48 5.66% | 20.33 -56.00% | ||||||
Market cap | 85,931 -85.72% | 601,762 12.23% | 536,163 -46.48% | ||||||
EV | 122,534 | 503,298 | 305,991 | ||||||
EBITDA | (167,301) | (172,324) | (106,935) | ||||||
EV/EBITDA | |||||||||
Interest | 13,314 | 8,213 | 40 | ||||||
Interest/NOPBT | |||||||||